What is Applied Genetic Technologies Earnings Yield (Joel Greenblatt) %?
Applied Genetic Technologies's Enterprise Value for the quarter that ended in Sep. 2022 was $4.28 Mil.
Applied Genetic Technologies's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was $-67.41 Mil. Applied Genetic Technologies's Earnings Yield (Joel Greenblatt) for the quarter that ended in Sep. 2022 was -1,666.67%.
The historical rank and industry rank for Applied Genetic Technologies's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
AGTC'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5089.8 Med: -7.92 Max: 4634.57
Current: -526.32
During the past 11 years, the highest Earnings Yield (Joel Greenblatt) of Applied Genetic Technologies was 4634.57%. The lowest was -5089.80%. And the median was -7.92%.
AGTC's Earnings Yield (Joel Greenblatt) % is not ranked
in the Biotechnology industry.
Industry Median: -14.77
vs AGTC: -526.32
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Applied Genetic Technologies's Forward Rate of Return (Yacktman) % for the quarter that ended in Sep. 2022 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Applied Genetic Technologies Earnings Yield (Joel Greenblatt) % Historical Data
The historical data trend for Applied Genetic Technologies's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Applied Genetic Technologies's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Applied Genetic Technologies's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Applied Genetic Technologies's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Applied Genetic Technologies's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Applied Genetic Technologiess Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Jun. 2022 is calculated as
Applied Genetic Technologies's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-67.41 Mil.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Applied Genetic Technologies Earnings Yield (Joel Greenblatt) % Related Terms
Thank you for viewing the detailed overview of Applied Genetic Technologies's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Applied Genetic Technologies (Applied Genetic Technologies) Business Description
Applied Genetic Technologies Corp is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa, achromatopsia (ACHM CNGB3 and ACHM CNGA3), and X-linked retinoschisis. In addition to its clinical trials, company has preclinical programs in optogenetics, adrenoleukodystrophy, which is a disease of the central nervous system, other ophthalmology, and otology indications. The optogenetics program is being developed in collaboration with Bionic Sight.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AGTC has been successfully added to your 